Announced details
JMDC data: more than 2.6 billion claims records and more than 94 million health checkup records as of March 2026
JMDC, 株式会社Zene and Maruho Co., Ltd. have launched a project to investigate genetic factors affecting skin physiology. JMDC and 株式会社Zene provide an integrated database of genetic testing data and claims data, together with data analytics capabilities, while Maruho provides expertise in dermatology. No capital or personnel relationships are disclosed.
株式会社Zene: Chiyoda-ku, Tokyo. Its representative director is Inoue Masahiro (井上 昌洋). Established in February 2020, it is a healthcare startup that provides the high-precision genetic testing service Zene360, a genomic analysis service, to insurers, companies and medical institutions., Maruho Co., Ltd.: A pharmaceutical company headquartered in Osaka City that conducts research, development, manufacturing and sales of prescription drugs and other products. Founded in 1915. Its representative director and president is Sugita Jun (杉田 淳).
As of March 2026, JMDC held more than 2.6 billion claims records and more than 94 million health checkup records.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Pep Up, Zene360, Integrated genetic testing data and claims data database |
| Counterparty | 株式会社Zene, Maruho Co., Ltd. |
| Counterparty overview | 株式会社Zene: Chiyoda-ku, Tokyo. Its representative director is Inoue Masahiro (井上 昌洋). Established in February 2020, it is a healthcare startup that provides the high-precision genetic testing service Zene360, a genomic analysis service, to insurers, companies and medical institutions., Maruho Co., Ltd.: A pharmaceutical company headquartered in Osaka City that conducts research, development, manufacturing and sales of prescription drugs and other products. Founded in 1915. Its representative director and president is Sugita Jun (杉田 淳). |
| Relationship with the Company | JMDC, 株式会社Zene and Maruho Co., Ltd. have launched a project to investigate genetic factors affecting skin physiology. JMDC and 株式会社Zene provide an integrated database of genetic testing data and claims data, together with data analytics capabilities, while Maruho provides expertise in dermatology. No capital or personnel relationships are disclosed. |
| Launch date | 29 June 2026 (project launch, actual) |
| Applicable area | Dermatology research, Drug Discovery, Disease research, Biomarker discovery, Market size estimation, Predictive analysis of complication risks |
| Location scale | As of March 2026, JMDC held more than 2.6 billion claims records and more than 94 million health checkup records. |
| Usage history | JMDC data: more than 2.6 billion claims records and more than 94 million health checkup records as of March 2026 |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The project combines Maruho’s dermatology expertise with genetic testing data, medical claims data and data analytics capabilities from JMDC and 株式会社Zene to elucidate the genetic effects on the skin characteristics of the Japanese population and the fundamental factors underlying skin pathophysiology, which have traditionally been difficult to analyze.